SymBio Pharmaceuticals Limited (SYMQY)

Market Cap	56.92M
Revenue (ttm)	14.15M
Net Income (ttm)	-29.23M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	23
Open	1.210
Previous Close	1.194
Day's Range	1.194 - 1.210
52-Week Range	0.900 - 1.420
Beta	0.28
RSI	94.91
Earnings Date	Jul 31, 2025

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and sales of pharmaceuticals and related operations to treat cancer, hematology, and viral infectious diseases in Japan and internationally. It offers SyB L-0501, an anti-cancer agent for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administration under the TREAKISYM name. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 108
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYMQY

Financial Performance

In 2024, SymBio Pharmaceuticals's revenue was 2.45 billion, a decrease of -56.13% compared to the previous year's 5.59 billion. Losses were -3.83 billion, 95.4% more than in 2023.

Financial numbers in JPY